Global Biosimilars Market Size, Share, Opportunities, COVID 19 Impact, And Trends By Type (Monoclonal Antibodies, Recombinant Proteins, Hormones, Others), By Disease (Infectious Disease, Oncology And Immunology, Respiratory, Genetic Disorders, Others), And By Geography - Forecasts From 2019 To 2024

Published:  May 2021 Report Code: KSI061611550 Pages: 130

The global biosimilar market is estimated to register a CAGR of 40.14% over the forecast period to reach a market size of US$19.151 billion by 2023 from US$2.528 billion in 2017. Biosimilars are defined as licensed and highly similar versions of biological drugs that have already been approved for use by regulatory bodies. The growth in the market may be attributed to the cost-effectiveness of the biosimilars when compared to reference biologics coupled with the patent expiration of the many blockbuster biologic drugs. By 2018, biologics worth more than US$68 billion annual sales will lose patent protection. Estimated patent and exclusivity expiry of a few of the blockbuster biologics are given below. Due to the structural complexity of the biosimilar drugs, multi-layered manufacturing, and risk of immunogenicity, separate regulatory pathways have been drafted to introduce them into the market.

Increasing investment by the companies for the development of biosimilars will also be the key factor driving the market. Recently in August 2018, Stada, a German biopharmaceutical company announced the investment of $ 115 million n biosimilar development by becoming a major shareholder in BioCeuticals, a venture capital-funded organization created by Stada to carry out its biosimilar programs. Similarly, Merck, in February 2018, invested $49 million to support the growing demand with new biopharmaceutical manufacturing and distribution centers in South Korea and India, while accelerating biosimilars manufacturing and development in China. Thus, the growing interest of the companies towards biosimilars will augment the market during the given time frame. New drug launches and collaborations have also helped the companies and bolstered the market. For instance, in January 2018, Biocon and Sandoz entered into a strategic partnership to develop the next generation of biosimilars in immunology and cancer. However, stringent regulations for the development and production of biosimilars could hinder biosimilar market growth.

Geographically, Europe holds the largest market share due to the presence of well-known biopharmaceutical companies such as Stada, Sandoz, AstraZeneca, Merck, etc.  Also, the well-defined regulatory framework for the approval of biosimilars and a rising number of product approvals coupled with well-developed healthcare infrastructure has further provided a boost to the European biosimilar market. Similarly, North America will also show robust growth during the forecast period owing to the increasing focus on product development coupled with the rising efforts from the manufacturers to tap the growth opportunities in the region.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining a faster and more efficient understanding of the global biosimilar market.

Major industry players profiled as part of the report are Sandoz, Stada Arzneimittel, Dr. Reddy's Laboratories, Biocad, and Samsung Bioepis among others.

Biosimilars Market Scope:

Report Metric Details
 Market size value in 2017  US$2.528 billion
 Market size value in 2023  US$19.151 billion
 Growth Rate  CAGR of 40.14% from 2017 to 2023
 Base year  2017
 Forecast period  2019–2024
 Forecast Unit (Value)  USD Billion
 Segments covered  Type, Disease, And Geography
 Regions covered  North America, South America, Europe, Middle East and Africa, Asia Pacific
 Companies covered  Samsung Bioepis, Stada Arzneimittel AG, Sandoz International GmbH (A Novartis   Company), Amgen Inc., Apotex Inc., BioCad, Dr. Reddy’s Laboratories Ltd., Biocon,   Boehringer Ingelheim International GmbH, Cinfa Biotech, Biogen International,   Hospira (A Pfizer Company)
 Customization scope  Free report customization with purchase

 

Segmentation

By Type

Monoclonal antibodies

Recombinant Proteins

Hormones

Others

 

By Disease

Infectious Disease

Oncology and Immunology

Respiratory

Genetic Disorders

Others

                               

By Geography

North America

US

Canada

Others

 

South America

Brazil

Argentina

Others

 

Europe

UK

Germany

France

Others

 

Middle East and Africa

Asia Pacific

China

India

Australia

Japan

Others


Frequently Asked Questions (FAQs)

Q1. What will be the biosimilar market size by 2023?
A1. The global biosimilar market is estimated to reach a total market size of US$19.151 billion by 2023.


Q2. What is the size of the global biosimilar market?
A2. Biosimilars Market was valued at US$2.528 billion in 2017.


Q3. What are the growth prospects for the biosimilar market?
A3. The biosimilar market is estimated to register a CAGR of 40.14% during the forecast period.


Q4. What factors are anticipated to drive the biosimilar market growth?
A4. The biosimilar market growth may be attributed to the cost-effectiveness of the biosimilars when compared to reference biologics coupled with the patent expiration of the many blockbuster biologic drugs.


Q5. Which region holds the largest market share in the biosimilar market?
A5. Geographically, Europe holds the largest share in the biosimilar market due to the presence of well-known biopharmaceutical companies such as Stada, Sandoz, AstraZeneca, Merck, etc.

1. Introduction
1.1. Market Definition
1.2. Scope of the Study
1.3. Currency
1.4. Assumptions
1.5. Base, and Forecast Years Timeline
2. Research Methodology
2.1. Research Design
2.2. Secondary Sources
2.3. Validation
3. Key Findings of the Study
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities and Market Trends
4.4. Market Segmentation
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Industry Value Chain Analysis
4.7. Industry Regulations
4.8. Scenario Analysis
5. Global Biosimilars Market Forecast by Type
5.1. Monoclonal Antibodies
5.2. Recombinant Proteins 
5.3. Hormones
5.4. Others
6. Global Biosimilars Market Forecast by Disease
6.1. Infectious Disease
6.2. Oncology and Immunology
6.3. Respiratory 
6.4. Genetic Disorders
6.5. Others 
7. Global Biosimilars Market Forecast by Geography
7.1. North America
7.1.1. The U.S
7.1.2. Canada
7.1.3. Mexico
7.1.4. Others
7.2. South America
7.2.1. Brazil 
7.2.2. Argentina
7.2.3. Others
7.3. Europe
7.3.1. U.K.
7.3.2. France
7.3.3. Germany
7.3.4. Italy
7.3.5. Others
7.4. Middle East and Africa
7.5. Asia Pacific 
7.5.1. China
7.5.2. India
7.5.3. Australia
7.5.4. Japan
7.5.5. Others 
8. Competitive intelligence
8.1. Market Share Analysis
8.2. Strategies of Key Players
8.3. Recent Investments and Deals
9. Company Profiles
9.1. Samsung Bioepis
9.1.1. Overview 
9.1.2. Financials
9.1.3. Product and Services 
9.1.4.  Recent Development
9.2. Stada Arzneimittel AG
9.2.1. Overview 
9.2.2. Financials
9.2.3. Product and Services 
9.2.4.  Recent Development
9.3. Sandoz International GmbH (A Novartis Company)
9.3.1. Overview 
9.3.2. Financials
9.3.3. Product and Services 
9.3.4.  Recent Development
9.4. Amgen Inc.
9.4.1. Overview 
9.4.2. Financials
9.4.3. Product and Services 
9.4.4.  Recent Development
9.5. Apotex Inc.
9.5.1. Overview 
9.5.2. Financials
9.5.3. Product and Services 
9.5.4.  Recent Development
9.6. BioCad
9.6.1. Overview 
9.6.2. Financials
9.6.3. Product and Services 
9.6.4.  Recent Development
9.7. Dr. Reddy’s Laboratories Ltd.
9.7.1. Overview 
9.7.2. Financials
9.7.3. Product and Services 
9.7.4.  Recent Development
9.8. Biocon
9.8.1. Overview 
9.8.2. Financials
9.8.3. Product and Services 
9.8.4.  Recent Development
9.9. Boehringer Ingelheim International GmbH 
9.9.1. Overview 
9.9.2. Financials
9.9.3. Product and Services 
9.9.4.  Recent Development
9.10. Cinfa Biotech
9.10.1. Overview 
9.10.2. Financials
9.10.3. Product and Services 
9.10.4.  Recent Development
9.11. Biogen International
9.11.1. Overview 
9.11.2. Financials
9.11.3. Product and Services 
9.11.4.  Recent Development
9.12. Hospira (A Pfizer Company)
9.12.1. Overview 
9.12.2. Financials
9.12.3. Product and Services 
9.12.4.  Recent Development
List of Tables
List of Figures 

Samsung Bioepis

Stada Arzneimittel AG

Sandoz International GmbH (A Novartis Company)

Amgen Inc.

Apotex Inc.

BioCad

Dr. Reddy’s Laboratories Ltd.

Biocon

Boehringer Ingelheim International GmbH 

Cinfa Biotech

Biogen International

Hospira (A Pfizer Company)

Pricing

Explore Custom Options available with this study:

  •  Request customization
  •  Buy sections of the study
  •  Buy country specific report
  •  Request excel, Historical data
  •  Subscription inquiry
  •  Request special pricing

Our Value Proposition

Analyst Support

All our studies come with 2 months of analyst support.


Confidentiality

We are in compliance with the global privacy laws.

Connect With Us